2017. Volume 7

CHINA FOOD AND DRUG NEWSLETTER

中国食品药品国际交流中心
SERVIER
施维雅（天津）制药有限公司

The ICH Assembly approved the CFDA as a new Regulatory Member

The International Council for Harmonization (ICH) met in Montreal, Canada from May 31 to June 1, 2017. The ICH Assembly approved the China Food and Drug Administration as a new Regulatory Member.

(June 19, 2017)

国家食品药品监督管理总局成为国际人用药品注册技术协调会成员

2017年5月31日至6月1日，国际人用药品注册技术协调会（ICH）2017年第一次会议在加拿大蒙特利尔召开。会议通过了中国国家食品药品监督管理总局的申请，总局成为国际人用药品注册技术协调会正式成员。（2017-06-19）

CFDA Issued the List of Reference Preparations of Generic Drugs (Fifth Batch) and the List of Reference Preparations of Generic Drugs (Sixth Batch)

After review and confirmation by Committee of Experts for Quality and Efficacy Consistency Evaluation of Generic Drugs, CFDA, on June 9, CFDA issued the List of Reference Preparations of Generic Drugs (Fifth Batch) and the List of Reference Preparations of Generic Drugs (Sixth Batch).

(June 9, 2017)

国家食品药品监督管理总局发布仿制药参比制剂目录（第五批）和仿制药参比制剂目录（第六批）

经国家食品药品监督管理总局仿制药质量和疗效一致性评价专家委员会审核确定，2017年6月9日，国家食品药品监督管理总局发布仿制药参比制剂目录第五批）和仿制药参比制剂目录（第六批）。（2017-06-09）

Notice of the General Office of CFDA on Printing and Issuing the *Confidentiality Provisions of CFDA of Drug and Medical Device Review and Approval Information*

With a view to maintaining the legitimate rights and interests of drug and medical device registration applicants, regulating and strengthening the administration on the confidentiality of drug and medical device review and approval information, CFDA organized to formulate the *Confidentiality Provisions of CFDA of Drug and Medical Device Review and Approval Information*, which are issued on June 2, 2017.

(June 2, 2017)

国家食品药品监督管理总局办公厅印发《国家食品药品监督管理总局药品医疗器械审评审批信息保密管理办法》

为维护药品、医疗器械注册申请人的合法权益，规范和加强药品、医疗器械审评审批信息保密管理，国家食品药品监督管理总局组织制定了《国家食品药品监督管理总局药品医疗器械审评审批信息保密管理办法》，于2017年6月2日 发布。（2017-06-02）

Published by
China Center for Food and Drug International Exchange
Servier (Tianjin) Pharmaceutical Co., Ltd.

CFDA Issued the *Announcement on Modifying the Package Inserts of Injections Containing Xylitol*

In accordance with the results of adverse drug reaction evaluation and in order to further ensure drug safety for the public, on June 1, CFDA issued the announcement on decision to modify such items as [Adverse Reactions], [Contraindications] and [Precautions] in the package inserts of injections containing xylitol (including xylitol injection, xylitol for injection, xylitol and sodium chloride injection, compound amino acid injection (18AA-V) and potassium aspartate and magnesium aspartate and xylitol injection).

(June 1, 2017)

国家食品药品监督管理总局发布《关于修订含木糖醇注射剂说明书的公告》

根据药品不良反应评估结果，为进一步保障公众用药安全，国家食品药品监督管理总局决定对含木糖醇注射剂（包括木糖醇注射液、注射用木糖醇、木糖醇氯化钠注射液、复方氨基酸注射液（18AA-V）和门冬氨酸钾镁木糖醇注射液）说明书【不良反应】、【禁忌】、【注意事项】等项进行修订。2017年6月1日，就有关事项发布公告。

（2017-06-01）

CFDA Issued the *Announcement on Modifying the Package Inserts of Compound Glycyrrhiza Oral Solution*

In accordance with the results of adverse drug reaction evaluation and in order to further ensure drug safety for the public, on June 1, CFDA issued the announcement on decision to modify such items as [Ingredients], [Adverse Reactions], [Contraindications] and [Precautions] in the package inserts of compound glycyrrhiza oral solution.

(June 1, 2017)

国家食品药品监督管理总局发布《关于修订复方甘草口服溶液说明书的公告》

根据药品不良反应评估结果，为进一步保障公众用药安全，国家食品药品监督管理总局决定对复方甘草口服溶液说明书【成份】、【不良反应】、【禁忌】、【注意事项】等项进行修订。2017年6月1日，就有关事项发布公告。

（2017-06-01）

CFDA Issued the Announcement on Information Tips for the Second Batch of Over-duplicated Drug Varieties

On June 2, 2017, CFDA issued the *Announcement on Information Tips for the Second Batch of Over-duplicated Drug Varieties*, and published the List of Over-duplicated Drug Varieties with the Approval Number for the Same Drug be Held by More Than 20 Enterprises. After monitoring and analyzing the sales of the drugs approved for marketing between 2013 and 2015, a total of 294 varieties were selected, covering 13 major varieties and 59 sub-varieties in clinical pharmacology and therapeutics classification.

CFDA reminded the relevant pharmaceutical manufacturers and R&D institutions to fully understand the market supply and demand situation, scientifically assess the drug R&D risks, and make careful investment decisions. The food and drug regulatory authorities of all provinces, autonomous regions and municipalities directly under the central government should strengthen the acceptance review, R&D site verification, and production site inspection of registration applications of related drugs; and take the initiative to publicize the announced over-duplicated drug varieties, to guide the enterprises' rational R&D and application.

(May 31, 2017)

国家食品药品监督管理总局发布第二批过度重复药品提示信息

2017年6月2日，国家食品药品监督管理总局发布《关于发布第二批过度重复药品提示信息的公告》，公布了同一药品已获批准文号企业数在20家以上的过度重复品种目录。在对已获批上市药品在2013~2015年间的销售情况进行监测分析后，共遴选出294个品种，涉及临床药理学和治疗学分类的13个大类、59个亚类。

国家食品药品监督管理总局提醒相关药品生产企业和研发机构，要充分了解市场供需状况，科学评估药品研发风险，慎重进行投资经营决策。各省、自治区、直辖市食品药品监督管理部门要加强对相关药品注册申请的受理审查、研制现场核查和生产现场检查，对已经公布的过度重复药品品种，主动做好宣传工作，引导企业理性研发和申报。

（2017-05-31）

CFDA Issued the *Announcement on the Opinions on Dealing with the Problems Identified in Drug Clinical Trial Data Verification*

According to relevant requirements of the *Opinions of the State Council on the Reform of the Review & Approval System for Drugs and Medical Devices* (GF [2015] No. 44), CFDA issued on July 22, 2015 the *Announcement on Carrying out Self-inspection & Verification of Drug Clinical Trial Data* ([2015] No. 117) to address the issues of inauthentic and even fraudulent clinical trial data found in certain drug registration applications, and organize the verification on clinical trial data of the drugs pending for review and approval of production or importation. Since then, CFDA has issued consecutively the *Announcement on the Disapproval of Registration Applications for 11 Drugs of 8 Enterprises* ([2015] No. 229), the *Announcement on the Disapproval of Registration Applications for 13 Drugs of 14 Enterprises* ([2015] No. 260), and the *Announcement on the Disapproval of Registration Applications for 6 Drugs of 7 Enterprises* ([2016] No. 92). Such problems as the inauthenticity, incompleteness and noncompliance of data exist in clinical trials of the drugs referred to in the said Announcements, they have violated the relevant provisions of the *Drug Administration Law of the People's Republic of China* and its Implementation Regulations, as well as the *Good Clinical Practice for Drugs* (GCP), and brought potential hazards to the safety and efficacy of drugs, seriously affecting public safety. Thereby CFDA issued on May 24, 2017 the *Announcement on the Opinions on Dealing with the Problems Identified in Drug Clinical Trial Data Verification* to notify relevant issues.

(May 24, 2017)

国家食品药品监督管理总局发布《关于药物临床试验数据核查有关问题处理意见的公告》

根据《国务院关于改革药品医疗器械审评审批制度的意见》（国发〔2015〕44号）的有关要求，针对部分药品注册申请中的临床试验数据不真实甚至弄虚作假问题，2015年7月22日，国家食品药品监督管理总局发布《关于开展药物临床试验数据自查核查工作的公告》（2015年第117号），组织对已申报生产或进口的待审药品开展临床试验数据核查工作。此后，国家食品药品监督管理总局先后发布《关于8家企业11个药品注册申请不予批准的公告》（2015年第229号）、《关于14家企业13个药品注册申请不予批准的公告》（2015年第260号）、《关于7家企业6个药品注册申请不予批准的公告》（2016年第92号）。上述公告中所述药物临床试验活动中存在的数据不真实、不完整和不规范等问题，违反了《中华人民共和国药品管理法》及其实施条例和《药物临床试验质量管理规范》（GCP）的有关规定，给药品安全性、有效性带来隐患，严重影响公共安全。2017年5月24日，国家食品药品监督管理总局发布《关于药物临床试验数据核查有关问题处理意见的公告》，将药物临床试验数据核查中发现的有关问题的处理意见进行了公告。（2017-05-24）

CFDA Issued the *Announcement on Self-inspection & Verification of Drug Clinical Trial Data for Registration Application*

On May 19, 2017, CFDA issued the *Announcement on Self-inspection & Verification of Drug Clinical Trial Data for Registration Application*, which reads as follows:

CFDA has decided to conduct clinical trial data verification for the newly received 44 registration applications for drugs whose clinical trials have been completed and which are under application for production or importation. Relevant matters are hereby announced as follows:

I. If the drug registration applicants found inauthenticity of clinical trial data before CFDA verification, they should take the initiative to apply for withdrawal of registration applications. CFDA should announce the list of applicants and varieties withdrawn without affixing accountability.

II. Center for Food and Drug Inspection, CFDA should publicize on its website the on-site verification plan, and inform the applicants of drug registrations and the local competent provincial food and drug

国家食品药品监督管理总局发布《关于药物临床试验数据自查核查注册申请情况的公告》

2017年5月19日，国家食品药品监督管理总局发布《关于药物临床试验数据自查核查注册申请情况的公告》，内容如下：

国家食品药品监督管理总局决定对新收到44个已完成临床试验申报生产或进口的药品注册申请进行临床试验数据核查。现将有关事宜公告如下：

一、在国家食品药品监督管理总局组织核查前，药品注册申请人自查发现药物临床试验数据存在真实性问题的，应主动撤回注册申请，国家食品药品监督管理总局公布其名单，不追究其责任。

二、国家食品药品监督管理总局食品药

administrations; 10 working days after the public notification, the Center should inform the date for on-site verification and no longer accept the applicants' withdrawal of drug registration applications.

III. CFDA should severely punish the applicants, responsible persons and managers of drug clinical trials and responsible persons of CRO found with frauds in clinical trial data on-site verification, and should hold responsible the inspectors of food and drug regulatory authorities who failed to perform their duties.

Annex: List of Registration Applications for 44 Drugs Subject to Self-inspection & Verification of Clinical Trial Data (omitted)

(May 19, 2017)

品审核查验中心将在其网站公示现场核查计划，并告知药品注册申请人及其所在地省级食品药品监管部门，公示10个工作日后该中心将通知现场核查日期，不再接受药品注册申请人的撤回申请。

三、国家食品药品监督管理总局将对药物临床试验数据现场核查中发现数据造假的申请人、药物临床试验责任人和管理人、合同研究组织责任人从重处理，并追究未能有效履职的食品药品监管部门核查人员的责任。

附件：44个药物临床试验数据自查核查注册申请清单(略)　　（2017-05-19）

CFDA Issued the Technical Guidelines for Extrapolation of Adult Drug Data to Pediatric Population

To further address the shortage and encourage the development of urgently needed pediatric drugs, and make the most of the existing data to reduce unnecessary pediatric research, CFDA organized to formulate the *Technical Guidelines for Extrapolation of Adult Drug Data to Pediatric Population*, which are based on data extrapolation and aim to optimize and enrich the pediatric drug information in package inserts to guide clinical medication. The Technical Guidelines were issued on May 18, 2017.

(May 18, 2017)

国家食品药品监督管理总局发布成人用药数据外推至儿科人群的技术指导原则

为解决儿科人群急需用药问题，进一步鼓励研制儿科用药，最大程度利用已有数据，减少不必要的儿科研究，通过数据外推完善和丰富说明书中儿科人群用药信息，指导临床用药，国家食品药品监督管理总局组织制定了《成人用药数据外推至儿科人群的技术指导原则》，于2017年5月18日发布。

（2017-05-18）

CFDA Issued 4 Guidelines Including the Guidelines for Development Site Verification for Quality and Efficacy Consistency Evaluation of Generic Drugs

To implement relevant requirements of the *Opinions of the General Office of the State Council on Carrying out Quality and Efficacy Consistency Evaluation of Generic Drugs* (GBF [2016] No. 8), and the *Announcement on Implementing Related Matters of the Opinions of the General Office of the State Council on Carrying out Quality and Efficacy Consistency Evaluation of Generic Drugs* (CFDA Announcement [2016] No. 106), CFDA organized to formulate the *Guidelines for Development Site Verification for Quality and Efficacy Consistency Evaluation of Generic Drugs*, the *Guidelines for Production Site Inspection for Quality and Efficacy Consistency Evaluation of Generic Drugs*, the *Guidelines for Clinical Trial Data Verification for Quality and Efficacy Consistency Evaluation of Generic Drugs* and the *Guidelines for For-cause Inspection for Quality and Efficacy Consistency Evaluation of Generic Drugs*, which were issued on May 18, 2017.

(May 18, 2017)

国家食品药品监督管理总局发布仿制药质量和疗效一致性评价研制现场核查指导原则等4个指导原则

为落实《国务院办公厅关于开展仿制药质量和疗效一致性评价的意见》（国办发〔2016〕8号）、《关于落实〈国务院办公厅关于开展仿制药质量和疗效一致性评价的意见〉有关事项的公告》（国家食品药品监督管理总局公告2016年第106号）的有关要求，国家食品药品监督管理总局组织制定了《仿制药质量和疗效一致性评价研究现场核查指导原则》《仿制药质量和疗效一致性评价生产现场检查指导原则》《仿制药质量和疗效一致性评价临床试验数据核查指导原则》《仿制药质量和疗效一致性评价有因检查指导原则》，于2017年5月18日发布。

（2017-05-18）

Food

CFDA Issued the *Technical Guidelines for Label Specifications for Formula Registration of Infant Formula Milk Powder (Interim)*

To further strengthen the formula registration of infant formula milk powder, and regulate the label management for formula registration of infant formula milk powder, in accordance with the *Provisions for Formula Registration of Infant Formula Milk Powder* (CFDA Order No. 26) and relevant national standards for food safety, CFDA formulated the *Technical Guidelines for Label Specifications for Formula Registration of Infant Formula Milk Powder (Interim)*, which were issued on May 24, 2017 and should come into effect as of the date of promulgation. (May 25, 2017)



食品

国家食品药品监督管理总局发布《婴幼儿配方乳粉产品配方注册标签规范技术指导原则（试行）》

为进一步加强婴幼儿配方乳粉产品配方注册工作，规范婴幼儿配方乳粉产品配方注册标签管理，依据《婴幼儿配方乳粉产品配方注册管理办法》(国家食品药品监督管理总局令第26号)及相关食品安全国家标准等规定，国家食品药品监督管理总局制定了《婴幼儿配方乳粉产品配方注册标签规范技术指导原则（试行）》，于2017年5月24日发布，自发布之日起施行。（2017-05-25）

CFDA Issued the *Application Dossier Items and Requirements for Formula Registration of Infant Formula Milk Powder (Interim) (2017 Revision)*

To further advance the formula registration of infant formula milk powder, on the basis of soliciting opinions from all social sectors, CFDA revised the *Application Dossier Items and Requirements for Formula Registration of Infant Formula Milk Powder (Interim)*, which were issued on May 24, 2017 and should come into effect as of the date of promulgation. (May 25, 2017)

国家食品药品监督管理总局发布《婴幼儿配方乳粉产品配方注册申请材料项目与要求（试行）（2017修订版）》

为进一步推进婴幼儿配方乳粉产品配方注册工作，在征求社会各界意见基础上，国家食品药品监督管理总局修订了《婴幼儿配方乳粉产品配方注册申请材料项目与要求（试行）》，于2017年5月24日发布，自发布之日起施行。（2017-05-25）

Medical Devices

Decision of the State Council on Revising the Regulations for the Supervision and Administration of Medical Devices Released

On May 4, 2017, *Decision of the State Council on Revising the Regulations for the Supervision and Administration of Medical Devices* (the State Council Decree No. 680) (hereinafter referred to as the Decision) Released, which should come into effect as of the date of promulgation. The Decision revised 10 articles including Article 18 of the Regulations for the Supervision and Administration of Medical Devices.

(May 19, 2017)

医疗器械

《国务院关于修改〈医疗器械监督管理条例〉的决定》公布

2017年5月4日，《国务院关于修改<医疗器械监督管理条例>的决定》（国务院令第680号）（以下简称《决定》）公布。《决定》对《医疗器械监督管理条例》的第十八条等十个条款进行了修订，自公布之日起施行。（2017-05-19）

The General Office of CFDA Issued the *Test Plan for the National Medical Devices Subject to Sampling Test in 2017*

In accordance with the requirements of the *Notice the General Office of CFDA on Carrying out Sampling Test for National Medical Devices in 2017* (SYJBXJ [2017] No. 41), on May 31, 2017, the General Office of CFDA issue the *Test Plan for the National Medical Devices Subject to Sampling Test in 2017*.

(May 31, 2017)

国家食品药品监督管理总局办公厅印发《2017年国家医疗器械抽检产品检验方案》

根据《食品药品监管总局办公厅关于开展2017年国家医疗器械抽检工作的通知》（食药监办械监〔2017〕41号）要求，2017年5月31日，国家食品药品监督管理总局办公厅印发了《2017年国家医疗器械抽检产品检验方案》。（2017-05-31）

CFDA Announcement on Issuing the *Guidelines for Registration Application Dossiers for Shelf Life of Non-active Implantable Medical Devices (2017 Revision)*

CFDA organized to formulate the *Guidelines for Registration Application Dossiers for Shelf Life of Non-active Implantable Medical Devices (2017 Revision)*, which are issued on May 26, 2017, to implement the *Regulations for the Supervision and Administration of Medical Devices* (State Council Decree No. 650) and the *Provisions for Medical Device Registration* (CFDA Order No. 4), strengthen the supervision and guidance of medical device registration management, further clarify the technical requirements for registration application dossiers for non-active implantable medical devices, guide registration applicants to prepare registration application dossiers for shelf life of non-active implantable medical devices. (May 26, 2017)

国家食品药品监督管理总局发布《无源植入性医疗器械货架有效期注册申报资料指导原则（2017年修订版）》

为贯彻实施《医疗器械监督管理条例》（中华人民共和国国务院令第650号）和《医疗器械注册管理办法》（国家食品药品监督管理总局令第4号），加强医疗器械注册管理工作监督指导工作，进一步明确无源植入性医疗器械产品注册申报资料的技术要求，指导注册申请人编制无源植入性医疗器械货架有效期注册申报资料，国家食品药品监督管理总局组织制订了《无源植入性医疗器械货架有效期注册申报资料指导原则（2017年修订版）》，于2017年5月26日发布。（2017-05-26）

Annual Report

2016 Annual Statistical Report on Food and Drug Supervision and Administration Published

On May 23, 2017, CFDA issued the *2016 Annual Statistical Report on Food and Drug Supervision and Administration*, which is excerpted as below:

• Drug manufacturing licensing

As of the end of November 2016, China has a total of 4,176 active substance and preparation manufacturers. In 2016, the numbers of pharmaceutical manufacturers, active substance and preparation manufacturers have all decreased, the underlying reason is that: in the manufacturing license renewal period, some enterprises failed to pass the GMP certification, and are thus pending for renewal of certificates.

• Drug distributing licensing

As of the end of November 2016, China has a total of 465,618 enterprises with the Drug Distributing License, of which there are 11,794 corporate wholesale enterprises, 1,181 unincorporated wholesale enterprises; 5,609 retail chain enterprises, 220,703 retail chain stores; and 226,331 retail mono-

年报

《2016年度食品药品监管统计年报》发布

2017年5月23日，国家食品药品监督管理总局发布《2016年度食品药品监管统计年报》。部分内容如下：

• 药品生产许可情况

截至2016年11月底，全国共有原料药和制剂生产企业4176家。2016年，药品生产企业数量以及原料药和制剂企业数量均有减少，这是因为生产企业许可证换证期间，一些企业由于未通过GMP认证，暂不具备换证条件而暂缓换证。

• 药品经营许可情况

截至2016年11月底，全国共有药品经营许可证持证企业465618家，其中法人批发企

drugstores.

• Drug registration

In 2016, a total of 4,011 applications for new drug clinical trial have been approved, along with 5 applications for NDA + approval number, and 13 applications for approval number; as well as 328 applications for clinical trial submitted in accordance with new drug application procedures have been approved.

In 2016, CFDA approved a total of 2,949 applications for clinical trial of generic drugs, and 207 applications for production.

In 2016, CFDA approved a total of 513 applications for clinical trial of imported drugs, and 28 applications for marketing.

In 2016, CFDA approved a total of 2,560 drug supplementary applications, and 578 applications for filing. Food and drug regulatory authorities of all provinces (autonomous regions and municipalities) have approved a total of 5,202 drug supplementary applications, and 16,039 applications for filing.

In 2016, CFDA approved a total of 782 applications for production of packaging materials and containers in direct contact with drugs, 924 applications for registration renewal, and 280 supplementary applications.

The report data are from the Food and Drug Administration Statistical Reporting System. The data reporting period ranges from December 1, 2015 to November 30, 2016.

(May 24, 2017)

业11794家、非法人批发企业1181家；零售连锁企业5609家，零售连锁企业门店220703家；零售单体药店226331家。

• 药品注册情况

2016年在新药审批工作中共批准新药临床4011件，新药证书及批准文号5件，批准文号13件；共批准按新药申请程序申报临床申请328件。

2016年共批准仿制药临床申请2949件，生产申请207件。

2016年共批准进口药品申请临床513件，上市28件。

2016年总局共批准药品补充申请2560件，备案578件。全国各省（区、市）局共批准药品补充申请5202件，备案16039件。

2016年总局共批准直接接触药品的包装材料和容器生产申请782件，再注册申请924件，补充申请280件。

本报告数据来源于《食品药品监督管理统计报表制度》。数据报告期为2015年12月1日至2016年11月30日。

（2017-05-24）

CFDA Issued the *Annual Report of Drug Inspection (2016)*

On May 31, 2017, CFDA issued the *Annual Report of Drug Inspection (2016)* in both Chinese and English versions, which elaborates the overview of inspections in 2016 and main findings therein, and analyzed the various bottlenecks and potential quality risks found in the inspections. The Report is divided into seven Parts, namely: Part I Pre-approval Inspection; Part II GMP Certification Inspection; Part III GMP Follow-up Inspection; Part IV Unannounced Inspection; Part V Overseas Inspection; Part VI GSP Unannounced Inspection; Part VII Observation of International Inspection.

《2016年度药品检查报告》发布

2017年5月31日，国家食品药品监督管理总局发布《2016年度药品检查报告》，报告包括中英文版，阐述了2016年药品检查情况及检查发现的主要问题，分析了各类检查发现的薄弱环节和潜在质量风险，报告共分七节，即第一节药品注册生产现场检查、第二节药品GMP认证检查、第三节药品GMP跟踪检查、第四节药品飞行检查、第五节进口药品境外检查、第六节药品流通检查和第七节国外机构GMP观察检查。

2016年完成各类药品检查任务一览表
Overview of the Inspections in 2016

检查工作 Inspections	检查企业数/品种数 Amount of inspected enterprises/varieties	派出组数 Amount of inspectorates	派出人数 Amount of inspectors
药品注册生产现场检查 Pre-approval inspection	34	43	178
药品GMP认证检查 GMP certification inspection	16	16	47
药品GMP跟踪检查 GMP follow-up inspection	204	197	704
药品飞行检查 Unannounced inspection	39	39	155
进口药品境外生产现场检查 Overseas inspection	7	7	31
药品流通检查 GSP unannounced inspection	50	50	77
国际观察检查 Observation of international inspection	81	81	85
合计Total	431	433	1277

(June 1, 2017)

（2017-06-01）

Overview of Consumer Goods Industry from January to March 2017

On June 1, 2017, the Ministry of Industry and Information Technology released the Overview of Consumer Goods Industry Operation from January to March 2017, which is excerpted are as follows:

I. Overall stability of production, wherein food and medicine saw a growth of 8.0% and 11.0%, respectively.

II. Relative stability of investment growth, wherein the food manufacturing industry and pharmaceutical manufacturing industry witnessed an increase of 0.7% and 8.1% year on year, respectively.

III. Key industries recorded higher sales-output ratios, wherein the food manufacturing industry and pharmaceutical manufacturing industry recorded 97.3% and 95%, respectively.

IV. Sluggish growth of exports, wherein food and medicine stepped up by 6.6% and 7.6%, respectively.

(Source: MIIT website, June 1, 2017)

2017年1－3月消费品工业运行总体情况

2017年6月1日，工业和信息化部发布2017年1－3月消费品工业运行总体情况。部分内容如下:

一、生产运行总体平稳。其中，食品、医药分别增长8.0%、11.0%。

二、投资增长相对平稳。其中，食品制造业、医药制造业同比分别增长0.7%、8.1%。

三、重点行业产销率较高。其中，食品制造业97.3%，医药制造业95%。

四、出口保持低速增长。其中，食品、医药同比分别增长6.6%、7.6%。

（摘自：工信部网站 2017-06-01）

Notes: • All Chinese information in the Newsletter is extracted from newspapers and the Internet. All English articles are translations from the Chinese version.
• For electronic version of the Newsletter please visit http://www.ccfdie.org

备 注： • Newsletter中所有中文信息摘自报刊及网络。英文均系中文翻译。
• 电子版Newsletter阅览请登录网站http://www.ccfdie.org

China Center for Food and Drug International Exchange (CCFDIE)
中国食品药品国际交流中心
Address: Room 1106, 11th Floor, Office Building B, Maples International Center, No. 32, Xizhimen North Street, Haidian District, Beijing, 100082, P.R.C.
中国北京市海淀区西直门北大街32号枫蓝国际中心B座写字楼11层1106室
邮编：100082
Tel: 010-8221 2866 Fax: 010-8221 2857
Email: ccfdie@ccfdie.org
Website: www.ccfdie.org

Servier (Tianjin) Pharmaceutical Co., Ltd.
施维雅（天津）制药有限公司
Address: 6 Floor, West Building, World Financial Center, No.1, East 3rd Ring Middle Road, Chaoyang District, 100020 Beijing, China
北京市朝阳区东三环中路1号环球金融中心西楼6层
邮政编码：100020
Tel: 010-6561 0341
Fax: 010-6561 0348
Website: www.servier.com.cn